Daily online adaptive radiotherapy for anal cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates the effectiveness of daily online adaptive radiotherapy (oART) for patients with anal cancer. It aims to determine if this approach can significantly reduce early gastrointestinal toxicity compared to traditional non-adaptive intensity modulated radiation therapy (IMRT). The study is a single-arm, prospective trial conducted at a single center, focusing on patients who are eligible for curative radiotherapy. Participants will receive daily adjustments to their treatment based on real-time imaging and anatomical changes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Biopsy-verified anal cancer
* Eligible for curative intended radiotherapy
* Written and oral consent

Exclusion Criteria:

* Other malignant disease within the past 5 years (excluding basal cell carcinoma)

Where it's running

• Oncology dept, Herlev and Gentofte Hospital
  Herlev, Denmark Recruiting

Study contacts

• Principal investigator: Eva S Serup-Hansen, MD, PhD — Herlev og Gentofte Hospital
• Study coordinator: Eva Serup-Hansen, MD, PhD
• Email: eva.serup-hansen@regionh.dk
• Phone: +4538689084

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Retifanlimab after chemoradiation for anal cancer

  This study tests whether retifanlimab can help people with anal squamous cell carcinoma who have completed chemoradiation and still have residual disease.

  Recruiting at 7 sites Phase 2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07927998

• Irreversible Electroporation for Recurrent Pelvic Tumors

  This study tests whether using irreversible electroporation (IRE) is safe and helps control recurrent pelvic tumors in adults who can’t have other local treatments.

  Recruiting Amsterdam UMC, location VUmc · Amsterdam, North Holland · NCT07782164

• HPV DNA-guided chemoradiation with Retifanlimab for locally advanced anal cancer

  This study tests whether adjusting chemoradiation doses based on HPV ctDNA results and adding Retifanlimab after CRT can improve outcomes for adults with new, locally advanced anal cancer.

  Recruiting Phase 2 Case Comprehensive Cancer Center · Cleveland, Ohio and 1 other locations · NCT07425054

• Vaginal DHEA to improve vaginal health after pelvic radiation

  This phase II trial tests whether daily vaginal DHEA can help reduce vaginal dryness, pain, and related symptoms in menopausal women after radiation for gynecologic, anal, or rectal cancers.

  Recruiting Phase 2 Ohio State University Comprehensive Cancer Center · Columbus, Ohio · NCT07407647

• Gynecological and sexual health after radiotherapy for anal cancer.

  See if vaginal problems and changes in sexual health are linked to radiation dose in women treated with chemoradiotherapy for anal cancer 6–36 months after treatment.

  Recruiting at 3 sites Aarhus University Hospital · Aarhus and 2 other locations · NCT07296237

• EVOLVE104 for advanced bladder and other squamous cell cancers

  This will try EVOLVE104, an experimental drug, in adults with advanced or metastatic bladder or other squamous cell cancers who have already tried or cannot take standard treatments.

  Recruiting at 16 sites Phase 1 EvolveImmune United, Inc · Duarte, California and 15 other locations · NCT07217171

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.